Literature DB >> 32247630

Phenome-wide association analysis suggests the APOL1 linked disease spectrum primarily drives kidney-specific pathways.

Archna Bajaj1, Andrea Ihegword2, Chengxiang Qiu3, Aeron M Small4, Wei-Qi Wei5, Lisa Bastarache5, QiPing Feng2, Rachel L Kember6, Marjorie Risman1, Roy D Bloom3, David L Birtwell7, Heather Williams7, Christian M Shaffer2, Jinbo Chen8, Regeneron Genetics Center9, Joshua C Denny10, Daniel J Rader11, C Michael Stein12, Scott M Damrauer13, Katalin Susztak14.   

Abstract

The relationship between commonly occurring genetic variants (G1 and G2) in the APOL1 gene in African Americans and different disease traits, such as kidney disease, cardiovascular disease, and pre-eclampsia, remains the subject of controversy. Here we took a genotype-first approach, a phenome-wide association study, to define the spectrum of phenotypes associated with APOL1 high-risk variants in 1,837 African American participants of Penn Medicine Biobank and 4,742 African American participants of Vanderbilt BioVU. In the Penn Medicine Biobank, outpatient creatinine measurement-based estimated glomerular filtration rate and multivariable regression models were used to evaluate the association between high-risk APOL1 status and renal outcomes. In meta-analysis of both cohorts, the strongest phenome-wide association study associations were for the high-risk APOL1 variants and diagnoses codes were highly significant for "kidney dialysis" (odds ratio 3.75) and "end stage kidney disease" (odds ratio 3.42). A number of phenotypes were associated with APOL1 high-risk genotypes in an analysis adjusted only for demographic variables. However, no associations were detected with non-renal phenotypes after controlling for chronic/end stage kidney disease status. Using calculated estimated glomerular filtration rate -based phenotype analysis in the Penn Medicine Biobank, APOL1 high-risk status was associated with prevalent chronic/end stage kidney disease /kidney transplant (odds ratio 2.27, 95% confidence interval 1.67-3.08). In high-risk participants, the estimated glomerular filtration rate was 15.4 mL/min/1.73m2; significantly lower than in low-risk participants. Thus, although APOL1 high-risk variants are associated with a range of phenotypes, the risks for other associated phenotypes appear much lower and in our dataset are driven by a primary effect on renal disease.
Copyright © 2020 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  chronic kidney disease; chronic kidney injury; renal pathology

Mesh:

Substances:

Year:  2020        PMID: 32247630      PMCID: PMC7265573          DOI: 10.1016/j.kint.2020.01.027

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  40 in total

1.  Association of trypanolytic ApoL1 variants with kidney disease in African Americans.

Authors:  Giulio Genovese; David J Friedman; Michael D Ross; Laurence Lecordier; Pierrick Uzureau; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Taras K Oleksyk; Andrea L Uscinski Knob; Andrea J Bernhardy; Pamela J Hicks; George W Nelson; Benoit Vanhollebeke; Cheryl A Winkler; Jeffrey B Kopp; Etienne Pays; Martin R Pollak
Journal:  Science       Date:  2010-07-15       Impact factor: 47.728

2.  Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.

Authors:  Frederick E Dewey; Viktoria Gusarova; Richard L Dunbar; Colm O'Dushlaine; Claudia Schurmann; Omri Gottesman; Shane McCarthy; Cristopher V Van Hout; Shannon Bruse; Hayes M Dansky; Joseph B Leader; Michael F Murray; Marylyn D Ritchie; H Lester Kirchner; Lukas Habegger; Alex Lopez; John Penn; An Zhao; Weiping Shao; Neil Stahl; Andrew J Murphy; Sara Hamon; Aurelie Bouzelmat; Rick Zhang; Brad Shumel; Robert Pordy; Daniel Gipe; Gary A Herman; Wayne H H Sheu; I-Te Lee; Kae-Woei Liang; Xiuqing Guo; Jerome I Rotter; Yii-Der I Chen; William E Kraus; Svati H Shah; Scott Damrauer; Aeron Small; Daniel J Rader; Anders Berg Wulff; Børge G Nordestgaard; Anne Tybjærg-Hansen; Anita M van den Hoek; Hans M G Princen; David H Ledbetter; David J Carey; John D Overton; Jeffrey G Reid; William J Sasiela; Poulabi Banerjee; Alan R Shuldiner; Ingrid B Borecki; Tanya M Teslovich; George D Yancopoulos; Scott J Mellis; Jesper Gromada; Aris Baras
Journal:  N Engl J Med       Date:  2017-05-24       Impact factor: 91.245

Review 3.  The Apolipoprotein L1 Gene and Cardiovascular Disease.

Authors:  Todd W Robinson; Barry I Freedman
Journal:  Methodist Debakey Cardiovasc J       Date:  2016 Oct-Dec

4.  Genetic variation in APOL1 associates with younger age at hemodialysis initiation.

Authors:  Zahra Kanji; Camille E Powe; Julia B Wenger; Chunmei Huang; Elizabeth Ankers; Dorothy A Sullivan; Gina Collerone; Neil R Powe; Marcello Tonelli; Ishir Bhan; Andrea J Bernhardy; Salvatore Dibartolo; David Friedman; Giulio Genovese; Martin R Pollak; Ravi Thadhani
Journal:  J Am Soc Nephrol       Date:  2011-10-13       Impact factor: 10.121

5.  Racial differences in the incidence of hypertensive end-stage renal disease (ESRD) are not entirely explained by differences in the prevalence of hypertension.

Authors:  W McClellan; E Tuttle; A Issa
Journal:  Am J Kidney Dis       Date:  1988-10       Impact factor: 8.860

6.  Next-generation genotype imputation service and methods.

Authors:  Sayantan Das; Lukas Forer; Sebastian Schönherr; Carlo Sidore; Adam E Locke; Alan Kwong; Scott I Vrieze; Emily Y Chew; Shawn Levy; Matt McGue; David Schlessinger; Dwight Stambolian; Po-Ru Loh; William G Iacono; Anand Swaroop; Laura J Scott; Francesco Cucca; Florian Kronenberg; Michael Boehnke; Gonçalo R Abecasis; Christian Fuchsberger
Journal:  Nat Genet       Date:  2016-08-29       Impact factor: 38.330

7.  Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial.

Authors:  Carl D Langefeld; Jasmin Divers; Nicholas M Pajewski; Amret T Hawfield; David M Reboussin; Diane E Bild; George A Kaysen; Paul L Kimmel; Dominic S Raj; Ana C Ricardo; Jackson T Wright; John R Sedor; Michael V Rocco; Barry I Freedman
Journal:  Kidney Int       Date:  2014-07-16       Impact factor: 10.612

8.  Transcription and translation of APOL1 variants.

Authors:  Samina Ejaz
Journal:  Biosci Rep       Date:  2017-10-11       Impact factor: 3.840

9.  Incidence and predictors of end stage renal disease among low-income blacks and whites.

Authors:  Loren Lipworth; Michael T Mumma; Kerri L Cavanaugh; Todd L Edwards; T Alp Ikizler; Robert E Tarone; Joseph K McLaughlin; William J Blot
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

10.  APOL1 Kidney Risk Variants and Cardiovascular Disease: An Individual Participant Data Meta-Analysis.

Authors:  Morgan E Grams; Aditya Surapaneni; Shoshana H Ballew; Lawrence J Appel; Eric Boerwinkle; L Ebony Boulware; Teresa K Chen; Josef Coresh; Mary Cushman; Jasmin Divers; Orlando M Gutiérrez; Marguerite R Irvin; Joachim H Ix; Jeffrey B Kopp; Lewis H Kuller; Carl D Langefeld; Michael S Lipkowitz; Kenneth J Mukamal; Solomon K Musani; Rakhi P Naik; Nicholas M Pajewski; Carmen A Peralta; Adrienne Tin; Christina L Wassel; James G Wilson; Cheryl A Winkler; Bessie A Young; Neil A Zakai; Barry I Freedman
Journal:  J Am Soc Nephrol       Date:  2019-08-05       Impact factor: 14.978

View more
  8 in total

1.  The key role of NLRP3 and STING in APOL1-associated podocytopathy.

Authors:  Junnan Wu; Archana Raman; Nathan J Coffey; Xin Sheng; Joseph Wahba; Matthew J Seasock; Ziyuan Ma; Pazit Beckerman; Dorottya Laczkó; Matthew B Palmer; Jeffrey B Kopp; Jay J Kuo; Steven S Pullen; Carine M Boustany-Kari; Andreas Linkermann; Katalin Susztak
Journal:  J Clin Invest       Date:  2021-10-15       Impact factor: 14.808

2.  Antisense oligonucleotides ameliorate kidney dysfunction in podocyte-specific APOL1 risk variant mice.

Authors:  Ya-Wen Yang; Bibek Poudel; Julia Frederick; Poonam Dhillon; Rojesh Shrestha; Ziyuan Ma; Junnan Wu; Koji Okamoto; Jeffrey B Kopp; Sheri L Booten; Danielle Gattis; Andrew T Watt; Matthew Palmer; Mariam Aghajan; Katalin Susztak
Journal:  Mol Ther       Date:  2022-04-20       Impact factor: 12.910

Review 3.  Apolipoprotein L1 and mechanisms of kidney disease susceptibility.

Authors:  Leslie A Bruggeman; John R Sedor; John F O'Toole
Journal:  Curr Opin Nephrol Hypertens       Date:  2021-05-01       Impact factor: 2.894

4.  Diagnosis, Education, and Care of Patients with APOL1-Associated Nephropathy: A Delphi Consensus and Systematic Review.

Authors:  Barry I Freedman; Wylie Burke; Jasmin Divers; Lucy Eberhard; Crystal A Gadegbeku; Rasheed Gbadegesin; Michael E Hall; Tiffany Jones-Smith; Richard Knight; Jeffrey B Kopp; Csaba P Kovesdy; Keith C Norris; Opeyemi A Olabisi; Glenda V Roberts; John R Sedor; Erika Blacksher
Journal:  J Am Soc Nephrol       Date:  2021-04-14       Impact factor: 14.978

5.  APOL1 at 10 years: progress and next steps.

Authors:  Barry I Freedman; Jeffrey B Kopp; Matthew G Sampson; Katalin Susztak
Journal:  Kidney Int       Date:  2021-03-29       Impact factor: 18.998

6.  Renal Histologic Analysis Provides Complementary Information to Kidney Function Measurement for Patients with Early Diabetic or Hypertensive Disease.

Authors:  Ghazal Z Quinn; Amin Abedini; Hongbo Liu; Ziyuan Ma; Andrew Cucchiara; Andrea Havasi; Jon Hill; Matthew B Palmer; Katalin Susztak
Journal:  J Am Soc Nephrol       Date:  2021-08-04       Impact factor: 10.121

7.  Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease.

Authors:  Lili Chan; Girish N Nadkarni; Fergus Fleming; James R McCullough; Patricia Connolly; Gohar Mosoyan; Fadi El Salem; Michael W Kattan; Joseph A Vassalotti; Barbara Murphy; Michael J Donovan; Steven G Coca; Scott M Damrauer
Journal:  Diabetologia       Date:  2021-04-02       Impact factor: 10.122

8.  APOL1 Risk Variants and Subclinical Cardiovascular Disease in Incident Hemodialysis Patients.

Authors:  Teresa K Chen; Jessica Fitzpatrick; Cheryl A Winkler; Elizabeth A Binns-Roemer; Celia P Corona-Villalobos; Bernard G Jaar; Stephen M Sozio; Rulan S Parekh; Michelle M Estrella
Journal:  Kidney Int Rep       Date:  2020-11-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.